Clinical Trial Update: A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial evaluating immunoradiotherapy combinations for metastatic solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Snippet

Sponsor: Genmab | Conditions: Non-CNS Tumor | Phase 1, Phase 2 | Status: TERMINATED